Navigation Links
Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm Holdings
Date:4/24/2008

PATERSON, N.J., April 24 /PRNewswire/ -- Amneal Pharmaceuticals, LLC is pleased to announce the execution of an Asset Purchase Agreement for Amneal's wholly-owned subsidiary, Amneal Pharmaceuticals of New York, LLC, to acquire the assets, facilities and business of Interpharm. The acquisition includes Interpharm's facilities on Long Island, New York as well as the intellectual property including ANDA's, technology and processes.

Amneal will use its strong leadership and financial position to fully realize the potential of Interpharm's powerful product line, ensure approval of its well defined development pipeline and leverage the unique manufacturing capabilities.

"Utilizing Amneal's financial strength, superb quality management, R&D and manufacturing expertise with Interpharm's outstanding facilities, leading market share and high value pipeline creates tremendous opportunities for rapid growth and exceptional customer satisfaction," said Chintu Patel, CEO of Amneal.

"Interpharm is excited about this acquisition of our assets. The financial stability brought by Amneal will allow it to springboard its rapid growth plans, and enhance the value to our loyal trading partners," added Jeff Weiss, Interpharm's executive vice president of sales and marketing.

Amneal will list assets of over one hundred products approved or filed with the USFDA and in development, controlled substance (C II-V) licensing and manufacturing, hormonal production suite, high potency production suite, soft gelatin capsules manufacturing, liquids manufacturing plant, 20 billion unit oral solid capacity and expansive R&D centers in New Jersey, New York and newly opened in India. Amneal president Chirag Patel comments, "This acquisition of intellectual and tangible assets provides Amneal the ability to accelerate its aggressive growth plans and rapidly broaden and deepen its product portfolio, while staying committed to full vertical integration and industry leading operations, R&D and Customer Service."

About Amneal Pharmaceuticals:

Amneal Pharmaceuticals LLC, headquartered in Paterson, NJ, is a USA-based firm that develops, manufacturers and distributes generic pharmaceutical products regulated and approved by the US FDA. Positioned as "Generic's New Generation," the company utilizes diverse R&D and manufacturing expertise to conceive breakthrough developments with lasting impact. Vigorous ANDA growth and broad product acquisitions are key features of Amneal's strategic growth plan, as is the company's commitment to building deep relationships with its customer base. Amneal delivers superior service levels, quality products, and dynamic value throughout the pharmaceutical industry.


'/>"/>
SOURCE Amneal Pharmaceuticals, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
2. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
3. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
4. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
5. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
6. RNs at Nine Catholic Healthcare West Hospitals Reach Agreement on New Master Pact
7. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
8. Biomoda, Inc. and Quintiles Announce Agreement for Regulatory Consulting
9. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
10. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
11. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology: